A comparison of the efficacy and toxic effects of sustained- vs immediate-release niacin in hypercholesterolemic patients.
about
Osteoarthritis and nutrition. From nutraceuticals to functional foods: a systematic review of the scientific evidenceThe safety of over-the-counter niacin. A randomized placebo-controlled trial [ISRCTN18054903]Optimal lipid modification: the rationale for combination therapyNicotinic acid receptor agonists differentially activate downstream effectorsThe metabolic syndromeA "hot" topic in dyslipidemia management--"how to beat a flush": optimizing niacin tolerability to promote long-term treatment adherence and coronary disease prevention.Hyperlipidemia associated with HIV protease inhibitor use: pathophysiology, prevalence, risk factors and treatment.Niacin: the evidence, clinical use, and future directions.Niacin: chemical forms, bioavailability, and health effects.Low high-density lipoprotein cholesterol: current status and future strategies for management.hyp loci control cell pattern formation in the vegetative mycelium of Aspergillus nidulans.Niacin-ER and lovastatin treatment of hypercholesterolemia and mixed dyslipidemia.The metabolic syndrome: pathophysiology, clinical relevance, and use of niacin.Ocular Effects of Niacin: A Review of the Literature.Liver fat reduction with niacin is influenced by DGAT-2 polymorphisms in hypertriglyceridemic patientsLipid-lowering agents that cause drug-induced hepatotoxicity.Safety and efficacy of extended-release niacin for the treatment of dyslipidaemia in patients with HIV infection: AIDS Clinical Trials Group Study A5148.Canadian Cardiovascular Society position statement--recommendations for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease.Acanthosis nigricans following single lung transplantation: a case report.Safety and efficacy evaluation of Ayurvedic treatment (Arjuna powder and Arogyavardhini Vati) in dyslipidemia patients: A pilot prospective cohort clinical study.Targeting multiple dyslipidemias with fixed combinations--focus on extended release niacin and simvastatinThe hypolipidemic activity of Ayurvedic medicine, Arogyavardhini vati in Triton WR-1339-induced hyperlipidemic rats: A comparison with fenofibrate.Functionally biased signalling properties of 7TM receptors - opportunities for drug development for the ghrelin receptor.The SLIM Study: Slo-Niacin® and Atorvastatin Treatment of Lipoproteins and Inflammatory Markers in Combined Hyperlipidemia.Novel patent publications on high-affinity nicotinic acid receptor agonists.The mechanism and mitigation of niacin-induced flushing.Important considerations for treatment with dietary supplement versus prescription niacin products.Combination treatment with atorvastatin plus niacin provides effective control of complex dyslipidemias: a literature review.Extended-release niacin with laropiprant : a review on efficacy, clinical effectiveness and safety.A reappraisal of the risks and benefits of treating to target with cholesterol lowering drugs.Acute Liver Failure Following One Year of Daily Consumption of a Sugar-Free Energy Drink.The cholesterol controversy."Isolated" low high-density lipoprotein cholesterol.Attenuation of niacin-induced prostaglandin D(2) generation by omega-3 fatty acids in THP-1 macrophages and Langerhans dendritic cellsNiacin for lipid disorders.Combination of low-dose niacin and pravastatin improves the lipid profile in diabetic patients without compromising glycemic control.Optimization and prediction of drug release from matrix tablets using response surface methodology and near infrared chemical imaging.NNMT activation can contribute to the development of fatty liver disease by modulating the NAD + metabolism.Metabolomic tissue signature in human non-alcoholic fatty liver disease identifies protective candidate metabolitesGuidelines for the Evaluation and Management of Dyslipidemia in Human Immunodeficiency Virus (HIV)-Infected Adults Receiving Antiretroviral Therapy: Recommendations of the HIV Medicine Association of the Infectious Disease Society of America and the
P2860
Q21195656-A6DFAF6F-83C3-4E72-9A3C-9E041FC5466BQ24797790-22239895-A059-4841-B04F-732B044DDDF1Q28219266-6AE848CD-01B2-4965-A4CD-B1947364D473Q28298974-45A08353-CBE2-4340-8250-A942356B38D8Q33569142-0B86CD9C-BE2A-4B80-BD58-748E7FD7FE58Q33765072-10887CC8-FC5C-481B-9607-0A9B0D1F2A07Q33926941-3437E364-DF44-49D4-B0C9-F8C040E960E0Q34228636-99680A6C-8807-401B-A3CE-C14C2869193BQ34278034-08C1D4AC-5E26-4008-A940-D4E07FB347C2Q34334846-824D57DA-E3F2-4624-9672-29F8F8378740Q34602604-B4A949A6-7C59-422C-9816-68A1BA7A6073Q35035100-AB4E09DE-BFAE-4B53-8FAF-A279CD88067AQ35637978-C77E9A44-75B4-4D5C-91A6-65D93625C3DBQ35690848-F3BFD1A1-5FC4-468E-AA95-C898814428A3Q35839709-12580B88-D0E7-452E-8A29-761EB4332C5BQ36103339-E9EC3972-CC79-411A-9306-A013BC1D0AF1Q36528526-4014A34C-3535-47E4-A6DA-54413E94F9E2Q36593266-26DEE460-C095-4D7C-BD15-A698B44608F2Q36606227-F6B2941B-D77E-4FE1-B938-416DD091E2E6Q36726951-9493A001-1286-4A6C-9A82-9873396E3B51Q37019920-C6C58420-E63E-48F6-AF4A-B585FC5F8887Q37290138-0ABE69AA-1C4C-4553-97FE-0DC362C22180Q37337832-8A606533-127F-466C-888E-BC655C01879CQ37375879-2E35AEE0-BD22-4EDD-A28D-19DBFF2DA014Q37529810-71FDCCC3-CE63-479A-8634-FF2260FF251DQ37582460-B93E04AE-E0D4-4337-9E07-050736587B8CQ37862929-2FE5F69E-AF13-47DE-B4B0-4C247385B9AFQ37982202-BFB76A48-BC3F-4388-A033-654F63F1061CQ38011204-2DC6F577-411F-485F-950E-FB01EC53BFA4Q38113494-63B08623-A157-4E98-88F8-BD867CAF2744Q40778283-42151ACC-E5E3-4BB6-9E72-B5449EB11D73Q41063495-C90F5255-320D-4D5F-A038-E84B866B42D1Q41316306-EEB84CAD-2C43-411E-8CB5-03E222975258Q42575304-9FDC44E4-294F-4DD5-9B30-B0E1529C2579Q49968075-E4A0051D-82BC-4E28-ABD3-F2CC92C05ABFQ51575259-B0D37168-92C5-4C9A-9B29-8338C2A957AFQ51615695-E750397F-EC60-48B8-97F3-8F9089C81E7FQ55395460-A178E78E-31FE-4B0B-BC7F-4359E1B6A6CAQ57568837-EE53F52C-6616-4AEA-B933-2CD4944AFBC7Q58375437-FF030998-7F03-4B06-AE1A-FDEF04E9A353
P2860
A comparison of the efficacy and toxic effects of sustained- vs immediate-release niacin in hypercholesterolemic patients.
description
1994 nî lūn-bûn
@nan
1994 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
1994 թվականի մարտին հրատարակված գիտական հոդված
@hy
1994年の論文
@ja
1994年論文
@yue
1994年論文
@zh-hant
1994年論文
@zh-hk
1994年論文
@zh-mo
1994年論文
@zh-tw
1994年论文
@wuu
name
A comparison of the efficacy a ...... hypercholesterolemic patients.
@ast
A comparison of the efficacy a ...... hypercholesterolemic patients.
@en
A comparison of the efficacy a ...... hypercholesterolemic patients.
@nl
type
label
A comparison of the efficacy a ...... hypercholesterolemic patients.
@ast
A comparison of the efficacy a ...... hypercholesterolemic patients.
@en
A comparison of the efficacy a ...... hypercholesterolemic patients.
@nl
prefLabel
A comparison of the efficacy a ...... hypercholesterolemic patients.
@ast
A comparison of the efficacy a ...... hypercholesterolemic patients.
@en
A comparison of the efficacy a ...... hypercholesterolemic patients.
@nl
P2093
P1476
A comparison of the efficacy a ...... hypercholesterolemic patients.
@en
P2093
J D Proctor
J M McKenney
V M Chinchili
P304
P356
10.1001/JAMA.1994.03510330050033
P407
P577
1994-03-01T00:00:00Z